These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 30138454)

  • 1. Charting the onset of Parkinson-like motor and non-motor symptoms in nonhuman primate model of Parkinson's disease.
    Choudhury GR; Daadi MM
    PLoS One; 2018; 13(8):e0202770. PubMed ID: 30138454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
    Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
    Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electroacupuncture Promotes Recovery of Motor Function and Reduces Dopaminergic Neuron Degeneration in Rodent Models of Parkinson's Disease.
    Lin JG; Chen CJ; Yang HB; Chen YH; Hung SY
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28837077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
    Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
    Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1-Methyl-4-phenyl-1,2,3,6 tetrahydropyridine/probenecid impairs intestinal motility and olfaction in the early stages of Parkinson's disease in mice.
    Choi JG; Huh E; Ju IG; Kim N; Yun J; Oh MS
    J Neurol Sci; 2018 Sep; 392():77-82. PubMed ID: 30031172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
    Mounsey RB; Mustafa S; Robinson L; Ross RA; Riedel G; Pertwee RG; Teismann P
    Exp Neurol; 2015 Nov; 273():36-44. PubMed ID: 26244281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of parkinson's disease, with emphasis on mice and nonhuman primates.
    Jakowec MW; Petzinger GM
    Comp Med; 2004 Oct; 54(5):497-513. PubMed ID: 15575363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational physiology of the basal ganglia in Parkinson's disease.
    Rivlin-Etzion M; Elias S; Heimer G; Bergman H
    Prog Brain Res; 2010; 183():259-73. PubMed ID: 20696324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective role of SIRT5 against motor deficit and dopaminergic degeneration in MPTP-induced mice model of Parkinson's disease.
    Liu L; Peritore C; Ginsberg J; Shih J; Arun S; Donmez G
    Behav Brain Res; 2015 Mar; 281():215-21. PubMed ID: 25541039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of motor symptoms in Parkinson's disease.
    Xia R; Mao ZH
    Neurosci Bull; 2012 Feb; 28(1):39-48. PubMed ID: 22233888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
    J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tauroursodeoxycholic Acid Improves Motor Symptoms in a Mouse Model of Parkinson's Disease.
    Rosa AI; Duarte-Silva S; Silva-Fernandes A; Nunes MJ; Carvalho AN; Rodrigues E; Gama MJ; Rodrigues CMP; Maciel P; Castro-Caldas M
    Mol Neurobiol; 2018 Dec; 55(12):9139-9155. PubMed ID: 29651747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Body side and predominant motor features at the onset of Parkinson's disease are linked to motor and nonmotor progression.
    Baumann CR; Held U; Valko PO; Wienecke M; Waldvogel D
    Mov Disord; 2014 Feb; 29(2):207-13. PubMed ID: 24105646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral phenotypes associated with MPTP induction of partial lesions in common marmosets (Callithrix jacchus).
    Phillips KA; Ross CN; Spross J; Cheng CJ; Izquierdo A; Biju KC; Chen C; Li S; Tardif SD
    Behav Brain Res; 2017 May; 325(Pt A):51-62. PubMed ID: 28219749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of long-term changes in circadian, locomotor, and cognitive functions in acute and chronic MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse models of Parkinson's disease.
    Fifel K; Dkhissi-Benyahya O; Cooper HM
    Chronobiol Int; 2013 Jul; 30(6):741-55. PubMed ID: 23758587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversible Pharmacological Induction of Motor Symptoms in MPTP-Treated Mice at the Presymptomatic Stage of Parkinsonism: Potential Use for Early Diagnosis of Parkinson's Disease.
    Khakimova GR; Kozina EA; Kucheryanu VG; Ugrumov MV
    Mol Neurobiol; 2017 Jul; 54(5):3618-3632. PubMed ID: 27194433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substantia Nigra Volume Dissociates Bradykinesia and Rigidity from Tremor in Parkinson's Disease: A 7 Tesla Imaging Study.
    Poston KL; Ua Cruadhlaoich MAI; Santoso LF; Bernstein JD; Liu T; Wang Y; Rutt B; Kerchner GA; Zeineh MM
    J Parkinsons Dis; 2020; 10(2):591-604. PubMed ID: 32250317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The understanding of Parkinson's disease through genetics and new therapies.
    Uwishema O; Onyeaka H; Badri R; Yücel AN; Korkusuz AK; Ajagbe AO; Abuleil A; Chaaya C; Alhendawi BHM; Chalhoub E
    Brain Behav; 2022 May; 12(5):e2577. PubMed ID: 35451243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical progression of Parkinson's disease.
    Poewe W; Mahlknecht P
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S28-32. PubMed ID: 20123553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.